Macro Trials Launches to Transform High-Value Therapeutics Clinical Trial Market
Summary
As part of its launch, the company also announced $6 million in seed funding for ongoing product development, expanding its clinical trial infrastructure across geographies and therapeutic areas, and scaling its study execution and data generation flywheel as it fills an urgent market need. These high failure rates continue to drive up the expense associated with bringing a new drug to market: it now costs approximately $2.7 billion to commercialize a high-value therapeutic, with 70% of that spend attributed to conducting clinical trials. Via its digitally powered infrastructure, Macro works closely with pharmaceutical companies, CROs, physicians, and health systems to design, plan, and execute clinical trials for high-value therapeutics with increased research velocity. Via its digitally powered infrastructure and "hub-and-spoke" distributed model, Macro partners with pharmaceutical companies, CROs, providers, and health systems to conduct trials for high-value therapeutics. Macros clinical trial intelligence platform and proprietary real-world evidence as a service (RWEaaS) product supports life sciences companies in all aspects of therapeutic research, development, and commercialization.